Drug intelligence / Profile preview

tinzaparin + dalteparin

Development stage: Unknown
Lead developer: LEO Pharma
Modality: Small Molecules
Administration: Subcutaneous, Intravenous

Overview

Tinzaparin and dalteparin are both low molecular weight heparins (LMWHs) used as anticoagulants. They are produced by different depolymerization processes of unfractionated heparin. Tinzaparin is produced by enzymatic depolymerization (heparinase digestion) while dalteparin is produced by controlled nitrous acid depolymerization. Both drugs work by potentiating the activity of antithrombin III, which inhibits the formation of factor Xa and thrombin, with a preference for inactivating factor Xa. They are used for the prevention and treatment of deep vein thrombosis, pulmonary embolism, and other thromboembolic conditions.

Brand names: Innohep + Fragmin

Targets

ATIII (Antithrombin III)F10 (Factor Xa)

Beyond the preview

Go deeper on tinzaparin + dalteparin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tinzaparin + dalteparin.

Explore the full profile